Overview
Respiratory molecular testing has expanded rapidly. Laboratories can now choose from focused multiplex assays targeting selected high-priority pathogens, broad syndromic panels detecting 20 or more organisms, and pneumonia-focused panels that may combine viral and bacterial detection with selected antimicrobial-resistance markers.
This creates an important question for clinical microbiologists and laboratory professionals: How broad should a respiratory molecular panel be?
There is no universal answer.
Focused and broad respiratory panels serve different testing needs. Focused panels can provide targeted detection of selected high-priority pathogens, while broad syndromic panels can expand diagnostic coverage within a consolidated workflow. In pneumonia—particularly severe community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)—the diagnostic question may extend beyond respiratory viruses to bacterial pathogens, lower-respiratory specimens and antimicrobial-resistance considerations.
The appropriate strategy therefore depends less on target count and more on the patient, syndrome, setting, specimen, epidemiology, workflow and intended use of the result.
Focused, broad and pneumonia-focused testing
There is no universally accepted target number separating a focused from a broad respiratory panel. It is more useful to consider the assay’s scope and intended purpose.
Focused Multiplex
Selected high-priority respiratory pathogens
Broad Syndromic
Wider respiratory differential
Pneumonia-Focused
Viral + bacterial ± selected resistance markers
There is no universally optimal panel size.
| Aspect | Focused Multiplex | Broad Syndromic | Pneumonia-Focused |
|---|---|---|---|
| Scope | Selected high-priority respiratory pathogens | Wider respiratory differential | Pathogens relevant to pneumonia, potentially including bacterial and viral targets |
| Primary objective | Answer a defined testing question | Consolidate broader pathogen investigation | Support investigation of lower-respiratory infection |
| Potential advantage | Concentrated testing for selected relevant targets | Expanded diagnostic coverage within one workflow | Rapid molecular information about important pneumonia pathogens |
| Resistance information | Usually not the primary purpose | Depends on assay | Some panels include selected resistance markers |
| Specimen considerations | Depends on assay | Often upper-respiratory, depending on intended use | May be designed around lower-respiratory specimens |
| Best fit | Depends on intended use and population | Depends on intended use and population | Depends on syndrome, patient population and intended use |
These are not simply small, medium and large versions of the same test. They may be designed to answer different diagnostic questions.
When does focused or broad testing make sense?
Focused multiplex testing can be appropriate when the diagnostic requirement is clearly defined and a selected group of pathogens provides the information needed.
One example is the simultaneous circulation of several high-priority respiratory viruses with overlapping clinical presentations. A focused multiplex assay can differentiate selected pathogens without requiring separate molecular tests.
Its limitation is equally clear:
A target not included in the panel cannot be detected by that panel.
Broad syndromic testing addresses a different need. It allows a wider respiratory differential to be investigated through a consolidated workflow and may be useful when the likely pathogen is less predictable or when detecting organisms outside a focused panel would provide meaningful information.
Potential applications can include selected hospitalised or immunocompromised patients, severe or unusual respiratory presentations, broader differential diagnosis, infection-prevention investigations and epidemiological applications.
Integrated sample-to-answer platforms may add another advantage: broader pathogen coverage within a simplified workflow rather than multiple sequential tests.
But increasing panel breadth also increases the information requiring interpretation.
Therefore:
More targets do not automatically mean more value—but fewer targets are not automatically better.
The objective is fit-for-purpose molecular testing.
Community-acquired pneumonia: severity changes the question
Community-acquired pneumonia illustrates why one testing strategy is unlikely to fit every patient.
An otherwise stable outpatient with CAP and a critically ill patient with severe CAP do not necessarily require the same microbiological investigation.
Current CAP pathways reflect this distinction. More extensive microbiological investigation becomes relevant in severe CAP and selected hospitalised patients, including respiratory culture and, where appropriate and available, molecular investigation.
The important principle is:
As disease severity and diagnostic uncertainty increase, the microbiological question may broaden.
A focused respiratory panel may therefore be appropriate in one CAP testing scenario, while a broader respiratory or pneumonia-focused investigation may provide greater value in another.
Panel breadth should follow the clinical and microbiological question—not the label “CAP” alone.
HAP and VAP are different microbiological problems
Clinical Context and the Microbiological Question — Conceptual Illustration
Community / CAP
Defined respiratory question
Severe CAP
Broader microbiological investigation may become relevant
HAP / VAP
Conceptual illustration — microbiological testing requirements depend on the patient, syndrome, severity, clinical setting and local protocols.
Hospital-acquired pneumonia and ventilator-associated pneumonia introduce additional considerations.
The pathogen distribution can differ from community respiratory infection, and antimicrobial resistance becomes particularly important. Depending on the patient, hospital environment and local epidemiology, organisms such as Staphylococcus aureus, Pseudomonas aeruginosa and other Gram-negative bacilli may be important considerations.
Prior antimicrobial exposure and local resistance patterns can further influence the differential.
HAP/VAP testing therefore cannot simply be reduced to:
“Use a broader respiratory viral panel.”
Instead, the laboratory may need to ask:
Which bacterial and viral pathogens matter? Which specimen should be tested? Is resistance information relevant? What conventional microbiology should accompany molecular testing?
HAP/VAP guidance emphasizes respiratory microbiology and the importance of local pathogen distribution and antimicrobial susceptibility data.
For clinical microbiologists, local epidemiology and the hospital antibiogram remain central to the diagnostic strategy.
A broad respiratory panel is not necessarily a pneumonia panel
This is an important distinction.
Two assays may each detect more than 20 targets while addressing very different diagnostic problems.
20+ Target Respiratory Panel
20+ TargetsRespiratory Panel
- Viruses + selected respiratory pathogens
- Upper-respiratory specimen depending on intended use
- Respiratory syndrome investigation
20+ Target Pneumonia Panel
20+ TargetsPneumonia Panel
- Bacterial + viral targets
- ± selected resistance markers
- Lower-respiratory specimen depending on intended use
- Pneumonia investigation
Target count alone does not define diagnostic scope.
A broad respiratory syndromic panel may focus primarily on respiratory viruses and selected bacterial pathogens and may be intended for upper-respiratory specimens.
A pneumonia-focused panel may instead be designed around lower-respiratory specimens and include bacterial pathogens relevant to pneumonia, potentially alongside viral targets and selected antimicrobial-resistance determinants.
So target count alone tells the laboratory relatively little.
A more useful comparison asks:
Which organisms are included? Which specimens are validated? Which syndrome and patient population is the assay intended for? Does it provide resistance-marker information? How will positive results be interpreted?
Specimen matters as much as panel breadth
The value of molecular testing depends not only on what the assay detects, but also on what specimen is tested.
Upper-respiratory specimens are widely used for molecular detection of respiratory viruses and other appropriate targets.
Pneumonia may require a different specimen strategy. Depending on the patient and setting, investigation can involve sputum, endotracheal aspirate, bronchoalveolar lavage or other appropriate lower-respiratory specimens.
This becomes particularly relevant in severe CAP, HAP and VAP.
Therefore:
A very broad panel performed on an inappropriate specimen for the diagnostic question is not made more appropriate simply because it detects more targets.
Molecular detection does not always establish causation
Molecular assays are highly sensitive tools for detecting microbial nucleic acid.
But detecting an organism and establishing that it is responsible for the patient’s current disease are not always the same thing.
Interpretation can be influenced by colonisation, prolonged nucleic-acid detection, co-detection, specimen quality, organism burden, previous antimicrobial therapy and the clinical presentation.
This becomes increasingly important when broad panels identify multiple organisms.
For clinical microbiologists, broader detection therefore brings both opportunity and responsibility:
More microbiological information can improve diagnostic insight, but it can also increase the need for expert interpretation.
Molecular Detection ≠ Causation
Detection of microbial nucleic acid should be interpreted in the context of the patient, specimen and syndrome.
What can antimicrobial-resistance genes tell us?
Some pneumonia-focused molecular panels detect selected antimicrobial-resistance genes alongside pathogen targets.
This may provide useful early information, but molecular resistance testing has limitations.
A resistance gene is not equivalent to a complete antimicrobial susceptibility profile. The relationship between genotype and phenotype depends on the organism, resistance mechanism and determinants included in the assay.
Likewise, absence of a particular resistance marker does not establish susceptibility to every relevant antimicrobial.
Resistance-marker results therefore need to be interpreted according to the assay’s intended use and alongside conventional microbiology where appropriate.
Resistance Gene ≠ Complete AST Profile
Molecular resistance markers can provide valuable early information but do not provide a complete phenotypic antimicrobial susceptibility profile.
Do molecular pneumonia panels replace culture and AST?
Molecular testing and conventional microbiology provide different but complementary information.
Molecular assays can rapidly detect selected pathogens and, depending on the assay, selected resistance determinants.
Culture can provide viable organisms for further identification, phenotypic antimicrobial susceptibility testing (AST) and additional epidemiological or microbiological investigation.
This distinction is particularly important in HAP/VAP, where antimicrobial resistance can strongly influence management.
Rather than asking whether molecular testing should replace culture, a more useful question is:
How can rapid molecular information and conventional microbiology work together within the diagnostic pathway?
Rapid Molecular Information
- Pathogen targets
- ± selected resistance markers
Conventional Microbiology
- Culture
- Phenotypic AST
- Viable isolate
Complementary Diagnostic Information
Diagnostic and antimicrobial stewardship
Diagnostic stewardship does not simply mean ordering fewer tests.
It means selecting and using diagnostics so that the resulting information is meaningful and appropriately interpreted.
For respiratory molecular testing, this can include deciding which patients to test, whether focused or broad testing is appropriate, which specimen to collect, how co-detections are interpreted and how molecular findings integrate with culture and susceptibility testing.
Broad testing and diagnostic stewardship are therefore not opposing ideas.
A broad panel can be entirely consistent with good diagnostic stewardship when its breadth addresses an appropriate diagnostic question.
Similarly, rapid pathogen identification can potentially support earlier antimicrobial decisions, but a rapid result does not automatically produce better antimicrobial use.
Its value depends partly on how results are integrated into clinical pathways, laboratory-clinician communication and antimicrobial-stewardship programmes.
Where does molecular point-of-care testing fit?
Panel breadth is only one dimension of respiratory molecular testing. The testing model also matters.
Integrated sample-to-answer systems can consolidate multiple molecular steps within a closed or simplified workflow, creating opportunities for testing closer to the point of need.
A broad molecular POCT or near-patient respiratory panel may therefore offer a different proposition from a conventional broad laboratory panel:
wide diagnostic coverage combined with a simplified integrated workflow.
This may reduce dependence on sequential testing and make broader molecular investigation accessible in settings where conventional multi-step workflows are difficult to implement.
Decentralisation, however, also creates responsibilities around operator training, quality control, result governance, connectivity and appropriate test utilisation.
The question becomes:
Which testing model delivers the required diagnostic information with appropriate quality and workflow for that setting?
Molecular Point-of-Care Testing — Conceptual Workflow
- 1Sample
- 2Integrated / Closed Workflow
- 3Multiplex Molecular Detection
- 4Result
Panel breadth and testing model are separate considerations.
A practical framework for clinical microbiologists
Instead of beginning with target count, respiratory molecular testing can be evaluated through eight questions:
NOT: Target Count → Assay Choice
Diagnostic Question → Appropriate Testing Strategy
1. Patient
Adult or paediatric? Outpatient or hospitalised? Immunocompetent or immunocompromised? General ward or critical care?
2. Syndrome
Upper respiratory infection? Influenza-like illness? CAP? Severe pneumonia? HAP? VAP?
3. Setting
Central laboratory? Emergency department? ICU? Decentralised laboratory? Point-of-care environment?
4. Specimen
Upper-respiratory specimen? Sputum? Endotracheal aspirate? Bronchoalveolar lavage? Another validated specimen?
5. Epidemiology
What is circulating? What is the local pathogen distribution? What does the hospital antibiogram show?
6. Diagnostic question
Are we differentiating selected high-priority pathogens, investigating a broad respiratory differential, investigating severe pneumonia, or seeking early information about bacterial pathogens or selected resistance mechanisms?
7. Testing scope
Focused multiplex? Broad syndromic testing? Pneumonia-focused molecular testing? A combination of molecular and conventional methods?
8. Interpretation and action
How will a positive or negative result be used? Is culture still required? Could antimicrobial or infection-control decisions be affected? Who will interpret complex or multiple detections?
The framework can therefore be summarised as:
Patient → Syndrome → Setting → Specimen → Epidemiology → Diagnostic Question → Testing Scope → Interpretation & Action
rather than:
Target Count → Assay Choice